155 related articles for article (PubMed ID: 27119111)
1. Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Ruf B; Berchtold S; Venturelli S; Burkard M; Smirnow I; Prenzel T; Henning SW; Lauer UM
Mol Ther Oncolytics; 2015; 2():15019. PubMed ID: 27119111
[TBL] [Abstract][Full Text] [Related]
2. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Ellerhoff TP; Berchtold S; Venturelli S; Burkard M; Smirnow I; Wulff T; Lauer UM
Int J Oncol; 2016 Nov; 49(5):1931-1944. PubMed ID: 27601235
[TBL] [Abstract][Full Text] [Related]
3. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
Fu M; Shi W; Li Z; Liu H
Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
[TBL] [Abstract][Full Text] [Related]
4. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
[TBL] [Abstract][Full Text] [Related]
5. Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.
Soukupova J; Bertran E; Peñuelas-Haro I; Urdiroz-Urricelqui U; Borgman M; Kohlhof H; Fabregat I
Oncotarget; 2017 Dec; 8(66):110367-110379. PubMed ID: 29299154
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic properties of resminostat for hepatocellular carcinoma.
Zhao J; Gray SG; Wabitsch M; Greene CM; Lawless MW
Oncoscience; 2018 May; 5(5-6):196-208. PubMed ID: 30035186
[TBL] [Abstract][Full Text] [Related]
7. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.
Berchtold S; Lampe J; Weiland T; Smirnow I; Schleicher S; Handgretinger R; Kopp HG; Reiser J; Stubenrauch F; Mayer N; Malek NP; Bitzer M; Lauer UM
J Virol; 2013 Mar; 87(6):3484-501. PubMed ID: 23302892
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat.
Peng X; Zhang D; Li Z; Fu M; Liu H
Biochem Biophys Res Commun; 2016 Sep; 477(4):556-562. PubMed ID: 27311860
[TBL] [Abstract][Full Text] [Related]
9. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
Tan DQ; Zhang L; Ohba K; Ye M; Ichiyama K; Yamamoto N
Eur J Immunol; 2016 Apr; 46(4):919-28. PubMed ID: 26763072
[TBL] [Abstract][Full Text] [Related]
10. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis.
Lampe J; Bossow S; Weiland T; Smirnow I; Lehmann R; Neubert W; Bitzer M; Lauer UM
Gene Ther; 2013 Nov; 20(11):1033-41. PubMed ID: 23719065
[TBL] [Abstract][Full Text] [Related]
11. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Enzenhofer E; Kadletz L; Stanisz I; Kotowski U; Seemann R; Schmid R; Thurnher D; Heiduschka G
Head Neck; 2017 May; 39(5):900-907. PubMed ID: 28170128
[TBL] [Abstract][Full Text] [Related]
12. Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.
May V; Berchtold S; Berger A; Venturelli S; Burkard M; Leischner C; Malek NP; Lauer UM
Oncol Lett; 2019 Nov; 18(5):5534-5542. PubMed ID: 31612061
[TBL] [Abstract][Full Text] [Related]
13. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses.
Zimmermann M; Armeanu S; Smirnow I; Kupka S; Wagner S; Wehrmann M; Rots MG; Groothuis GM; Weiss TS; Königsrainer A; Gregor M; Bitzer M; Lauer UM
Int J Oncol; 2009 May; 34(5):1247-56. PubMed ID: 19360338
[TBL] [Abstract][Full Text] [Related]
14. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
15. Primary resistance phenomena to oncolytic measles vaccine viruses.
Noll M; Berchtold S; Lampe J; Malek NP; Bitzer M; Lauer UM
Int J Oncol; 2013 Jul; 43(1):103-12. PubMed ID: 23612727
[TBL] [Abstract][Full Text] [Related]
16. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Muscolini M; Castiello L; Palermo E; Zevini A; Ferrari M; Olagnier D; Hiscott J
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092575
[TBL] [Abstract][Full Text] [Related]
17. Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.
Klose C; Berchtold S; Schmidt M; Beil J; Smirnow I; Venturelli S; Burkard M; Handgretinger R; Lauer UM
BMC Cancer; 2019 Dec; 19(1):1172. PubMed ID: 31795974
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
Tsilimigras DI; Ntanasis-Stathopoulos I; Moris D; Spartalis E; Pawlik TM
Surg Oncol; 2018 Dec; 27(4):611-618. PubMed ID: 30449480
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus.
Scheicher NV; Berchtold S; Beil J; Smirnow I; Schenk A; Lauer UM
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339240
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity.
Ying L; Cheng H; Xiong XW; Yuan L; Peng ZH; Wen ZW; Ka LJ; Xiao X; Jing C; Qian TY; Liang GZ; Mei YG; Bo ZW; Liang P
Oncotarget; 2017 Apr; 8(15):24694-24705. PubMed ID: 28445966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
